New stem cell transplant aims to cut dangerous side effects in blood cancer patients

NCT ID NCT05735717

Recruiting now Disease control Sponsor: Masonic Cancer Center, University of Minnesota Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a special stem cell transplant for children and adults with blood cancers like leukemia. The transplant uses stem cells that have had certain immune cells removed to lower the risk of graft-versus-host disease, a serious complication. About 70 participants will receive chemotherapy and the modified stem cells. The goal is to see if this approach is safe and helps the body accept the new cells.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: T cell receptor alpha/beta depleted stem cells
What this could lead to: If successful, this approach could offer a safer stem cell transplant option for people with blood cancers, reducing the risk of graft-versus-host disease.
What could go wrong: This is an early phase II study with only 70 participants, so results may not apply to everyone. There are still risks like graft failure, infection, or the cancer returning.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute leukemia acute lymphoblastic leukemia acute myeloid leukemia beta thalassemia central nervous system leukemia chromosomal disorder Chromosome 7, monosomy Chromosome Aberrations hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm influenza juvenile myelomonocytic leukemia lymphoblastic lymphoma myelodysplastic syndrome myelodysplastic syndrome with excess blasts Neoplasm, Residual neurofibromatosis type 1 non-Hodgkin lymphoma Precursor Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LEUKEMIA ACUTE LYMPHOBLASTIC LEUKEMIA ACUTE MYELOID LEUKEMIA AML CBL GENE MUTATION CHROMOSOME ABNORMALITY CNS LEUKEMIA CYTOGENETIC ABNORMALITY FETAL HEMOGLOBIN HEMATOLOGIC MALIGNANCY HIGH GRADE NON-HODGKIN'S LYMPHOMA, ADULT INTRACHROMOSOMAL AMPLIFICATION OF CHROMOSOME 21 JUVENILE MYELOMONOCYTIC LEUKEMIA LYMPHOBLASTIC LYMPHOMA MINIMAL RESIDUAL DISEASE MONOSOMY 7 MYELODYSPLASIA N-RAS GENE AMPLIFICATION NEUROFIBROMATOSIS 1 NF1 MUTATION PTPN11 GENE MUTATION REMISSION SOMATIC MUTATION TP53

Contacts and locations

Locations

University of Minnesota Masonic Cancer Center
RECRUITING

Minneapolis, Minnesota, 55455, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.